B3 7. (Twice Amended) The ^{13}C-labeled oligosaccharide or polysaccharide or a salt thereof according to claim 5, which is a cyclic oligosaccharide or polysaccharide.

B4 9. (Amended) (Twice Amended) The ^{13}C-labeled oligosaccharide or polysaccharide or a salt thereof according to claim 5, which is a ^{13}C-cyclodextrin or β-galactosyl-^{13}C- maltooligosaccharide.--

Please add claims 43 to 63.

B5 --43. (New) A method of measuring pancreatic exocrine function, comprising:

administering to a subject to be tested for pancreatic exocrine function, a ^{13}C- or ^{14}C-labeled oligosaccharide or polysaccharide or a salt thereof or a derivative thereof other than ^{13}C-starch; and

measuring a ^{13}C content in an exhaled CO_2 of the subject to determine the level of pancreatic exocrine function.

44. (New) The method of measuring pancreatic exocrine function according to claim 43, wherein the ^{13}C- or ^{14}C-labeled oligosaccharide or polysaccharide or salt thereof or derivative thereof is hydrolyzed with α-amylase.

45. (New) The method of measuring pancreatic exocrine function according to claim 44, wherein the ^{13}C- or ^{14}C- labeled oligosaccharide or polysaccharide or salt thereof or derivative thereof is not hydrolyzed with α- glucosidase.

46. (New) The method of measuring pancreatic exocrine function according to claims 43, wherein the ^{13}C- or ^{14}C- labeled oligosaccharide or polysaccharide is a linear or branched oligosaccharide or polysaccharide.

AS

47. (New) The method of measuring pancreatic exocrine function according to claim 46, wherein the ^{13}C- or ^{14}C- labeled oligosaccharide or polysaccharide is modified at the non-reducing terminal.

48. (New) The method of measuring pancreatic exocrine function according to claims 43, wherein the ^{13}C- or ^{14}C- labeled oligosaccharide or polysaccharide is a cyclic oligosaccharide or polysaccharide.

49. (New) The method of measuring pancreatic exocrine function comprising:

administering to a subject to be tested for pancreatic exocrine function, a ^{13}C- or ^{14}C-labeled inclusion complex or a salt thereof having a cyclodextrin or a modified derivative thereof as a host molecule.

50. (New) The method of measuring pancreatic exocrine function according to any one of claims 43, wherein the pancreatic exocrine function to be diagnosed is the ability of the pancreas to secrete *a*- amylase.

51. (New) The method of measuring pancreatic exocrine function according to claims 43, wherein the pancreatic exocrine function to be diagnosed is the ability of the pancreas to secrete *a* amylase and at least one pancreatic exocrine enzyme other than *a*-amylase.

52. (New) A method of measuring pancreatic exocrine function, comprising:

administering to a subject to be tested for pancreatic exocrine function, ^{13}C-cyclodextrin or at least one sugar molecule constituting the oligosaccharide or polysaccharide being modified with at least one modifying group, wherein said sugar molecule or modifying group is ^{13}C-labeled, and said modifying group is selected from a group consisting of a galactosyl group, a digalactosyl group, an alkoxyl group, a carbamoyl group, a pyrimidino group, an ethylidene group, and a benzylidene group; and

measuring a ^{13}C content in an exhaled CO_2 of the subject to determine the level of pancreatic exocrine function.

A5

53. (New) The method according to claim 52, further comprising:

administering the oligosaccharide or polysaccharide, or salt thereof orally.

54. (New) The method according to claim 52, wherein the administered ^{13}C-labeled oligosaccharide or polysaccharide, or salt thereof is decarboxylated to generate $^{13}CO_2$ after a digestion by pancreatic secreted enzymes.

55. (New) The method according to claim 54, wherein the pancreatic secreted enzyme is α-amylase.

56. (New) The method according to claim 52, further comprising:

providing said oligosaccharide comprising polymerized monosaccharides of two to ten residues long.

57. (New) The method according to claim 52, further comprising:

providing said polysaccharide comprising polymerized monosaccharides of at least ten residues long.

58. (New) A method of determining whether a subject has a reduced pancreatic exocrine function, comprising:

administering to a subject to be tested for pancreatic exocrine function, ^{13}C-cyclodextrin or at least one sugar molecule constituting the oligosaccharide or polysaccharide being modified with at least one modifying group, wherein said sugar molecule or modifying group is ^{13}C-labeled, and said modifying group is selected from a group consisting of a galactosyl group, a digalactosyl group, an alkoxyl group, a carbamoyl group, a pyrimidino group, an ethylidene group, and a benzylidene group;

measuring a ^{13}C content in an exhaled CO_2 of the subject; and

comparing the ^{13}C content in the exhaled CO_2 of the subject to the level of a ^{13}C content in the exhaled CO_2 of a healthy control subject who was administered an equivalent amount of

A5

the ^{13}C-labeled oligosaccharide or polysaccharide or the pharmaceutically acceptable salt thereof,

wherein the reduced ^{13}C in the exhaled CO_2 of the subject is an indication that the subject has a reduced pancreatic exocrine function.

59. (New) The method according to claim 58, further comprising:

administering the oligosaccharide or polysaccharide, or salt thereof orally.

60. (New) The method according to claim 58, wherein the administered ^{13}C-labeled oligosaccharide or polysaccharide, or salt thereof is decarboxylated to generate $^{13}CO_2$ after a digestion by pancreatic secreted enzymes.

61. (New) The method according to claim 60, wherein the pancreatic secreted enzyme is α-amylase.

62. (New) The method according to claim 58, further comprising:

providing said oligosaccharide comprising polymerized monosaccharides of two to ten residues long.

63. (New) The method according to claim 58, further comprising:

providing said polysaccharide comprising polymerized monosaccharides of at least ten residues long. --

In the drawings:

Please find enclosed corrected drawings.